Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications

Michael T. Lotze, Mary C. Custer, Ellen S. Bolton, Eric A. Wiebke, Yutaka Kawakami, Steven A. Rosenberg

Research output: Contribution to journalArticle

Abstract

The use of interleukin 2-based immunotherapies for cancer has been associated with significant resonses in tumor models in both mouse and humans. Further definition of the elements responsible for response is now possible. It appears that the respnse is associated with T-cell infiltration of the tumor, and transfer of tumor-infiltrating lymphocytes expanded in tissue culture with interleukin 2 is associated with significant antitumor effects. Further expansion of cultured human melanoma tumor-infiltrating lymphocytes with suppression of lymphokine-activated killer activity as well as the modulation of monocyte activity by interleukin 4 suggests that this cytokine may be clinically useful alone or in combination with interleukin 2. Other means of enhancing the activity of interleukin 2-based immunotheraphy are suggested by the finding that tumor cell susceptibility to lysis by natural killer cells is depressed following treatment with interferon γ and tumor necrosis factor, but susceptibility to lysis by tumor-infiltrating lymphocytes is markedly enhanced. Further development of these therapies will require innovative interpretation and application of findings related to the processing and presentation of human tumor antigens and the nature of tumor antigens and careful analysis of they T-cell receptor in antitumor effectors.

Original languageEnglish (US)
Pages (from-to)198-207
Number of pages10
JournalHuman Immunology
Volume28
Issue number2
DOIs
StatePublished - 1990
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Interleukin-2
Neoplasm Antigens
Neoplasms
Lymphokines
Response Elements
Therapeutics
T-Cell Antigen Receptor
Natural Killer Cells
Interleukin-4
Immunotherapy
Interferons
Monocytes
Melanoma
Tumor Necrosis Factor-alpha
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Lotze, M. T., Custer, M. C., Bolton, E. S., Wiebke, E. A., Kawakami, Y., & Rosenberg, S. A. (1990). Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications. Human Immunology, 28(2), 198-207. https://doi.org/10.1016/0198-8859(90)90020-P

Mechanisms of immunologic antitumor therapy : lessons from the laboratory and clinical applications. / Lotze, Michael T.; Custer, Mary C.; Bolton, Ellen S.; Wiebke, Eric A.; Kawakami, Yutaka; Rosenberg, Steven A.

In: Human Immunology, Vol. 28, No. 2, 1990, p. 198-207.

Research output: Contribution to journalArticle

Lotze, MT, Custer, MC, Bolton, ES, Wiebke, EA, Kawakami, Y & Rosenberg, SA 1990, 'Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications', Human Immunology, vol. 28, no. 2, pp. 198-207. https://doi.org/10.1016/0198-8859(90)90020-P
Lotze, Michael T. ; Custer, Mary C. ; Bolton, Ellen S. ; Wiebke, Eric A. ; Kawakami, Yutaka ; Rosenberg, Steven A. / Mechanisms of immunologic antitumor therapy : lessons from the laboratory and clinical applications. In: Human Immunology. 1990 ; Vol. 28, No. 2. pp. 198-207.
@article{7695260e422e4545a45c43fa430e25c9,
title = "Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications",
abstract = "The use of interleukin 2-based immunotherapies for cancer has been associated with significant resonses in tumor models in both mouse and humans. Further definition of the elements responsible for response is now possible. It appears that the respnse is associated with T-cell infiltration of the tumor, and transfer of tumor-infiltrating lymphocytes expanded in tissue culture with interleukin 2 is associated with significant antitumor effects. Further expansion of cultured human melanoma tumor-infiltrating lymphocytes with suppression of lymphokine-activated killer activity as well as the modulation of monocyte activity by interleukin 4 suggests that this cytokine may be clinically useful alone or in combination with interleukin 2. Other means of enhancing the activity of interleukin 2-based immunotheraphy are suggested by the finding that tumor cell susceptibility to lysis by natural killer cells is depressed following treatment with interferon γ and tumor necrosis factor, but susceptibility to lysis by tumor-infiltrating lymphocytes is markedly enhanced. Further development of these therapies will require innovative interpretation and application of findings related to the processing and presentation of human tumor antigens and the nature of tumor antigens and careful analysis of they T-cell receptor in antitumor effectors.",
author = "Lotze, {Michael T.} and Custer, {Mary C.} and Bolton, {Ellen S.} and Wiebke, {Eric A.} and Yutaka Kawakami and Rosenberg, {Steven A.}",
year = "1990",
doi = "10.1016/0198-8859(90)90020-P",
language = "English (US)",
volume = "28",
pages = "198--207",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Mechanisms of immunologic antitumor therapy

T2 - lessons from the laboratory and clinical applications

AU - Lotze, Michael T.

AU - Custer, Mary C.

AU - Bolton, Ellen S.

AU - Wiebke, Eric A.

AU - Kawakami, Yutaka

AU - Rosenberg, Steven A.

PY - 1990

Y1 - 1990

N2 - The use of interleukin 2-based immunotherapies for cancer has been associated with significant resonses in tumor models in both mouse and humans. Further definition of the elements responsible for response is now possible. It appears that the respnse is associated with T-cell infiltration of the tumor, and transfer of tumor-infiltrating lymphocytes expanded in tissue culture with interleukin 2 is associated with significant antitumor effects. Further expansion of cultured human melanoma tumor-infiltrating lymphocytes with suppression of lymphokine-activated killer activity as well as the modulation of monocyte activity by interleukin 4 suggests that this cytokine may be clinically useful alone or in combination with interleukin 2. Other means of enhancing the activity of interleukin 2-based immunotheraphy are suggested by the finding that tumor cell susceptibility to lysis by natural killer cells is depressed following treatment with interferon γ and tumor necrosis factor, but susceptibility to lysis by tumor-infiltrating lymphocytes is markedly enhanced. Further development of these therapies will require innovative interpretation and application of findings related to the processing and presentation of human tumor antigens and the nature of tumor antigens and careful analysis of they T-cell receptor in antitumor effectors.

AB - The use of interleukin 2-based immunotherapies for cancer has been associated with significant resonses in tumor models in both mouse and humans. Further definition of the elements responsible for response is now possible. It appears that the respnse is associated with T-cell infiltration of the tumor, and transfer of tumor-infiltrating lymphocytes expanded in tissue culture with interleukin 2 is associated with significant antitumor effects. Further expansion of cultured human melanoma tumor-infiltrating lymphocytes with suppression of lymphokine-activated killer activity as well as the modulation of monocyte activity by interleukin 4 suggests that this cytokine may be clinically useful alone or in combination with interleukin 2. Other means of enhancing the activity of interleukin 2-based immunotheraphy are suggested by the finding that tumor cell susceptibility to lysis by natural killer cells is depressed following treatment with interferon γ and tumor necrosis factor, but susceptibility to lysis by tumor-infiltrating lymphocytes is markedly enhanced. Further development of these therapies will require innovative interpretation and application of findings related to the processing and presentation of human tumor antigens and the nature of tumor antigens and careful analysis of they T-cell receptor in antitumor effectors.

UR - http://www.scopus.com/inward/record.url?scp=0025279817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025279817&partnerID=8YFLogxK

U2 - 10.1016/0198-8859(90)90020-P

DO - 10.1016/0198-8859(90)90020-P

M3 - Article

C2 - 2190952

AN - SCOPUS:0025279817

VL - 28

SP - 198

EP - 207

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 2

ER -